A Phase II Study of ZD 1839 (NSC 715055) [gefitinib] for Patients With First Relapse Glioblastoma Multiforme
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.